Intas launches cheaper drug to treat chronic ITP

Our Bureau Ahmedabad | Updated on July 10, 2019 Published on July 10, 2019

Becomes first to launch Romiplostim in India

Drug-maker Intas Pharmaceuticals Ltd announced the launch of Romiplostim in India under the brand name Romy, making therapy for chronic immune thrombocytopenia (ITP) affordable for patients. ITP is an autoimmune blood disorder which leads to low platelet counts.

The newly-launched drug will cost just one-fifth of the price of the current nmedication: The currently available care therapy for chronic ITP costs approximately ₹60,000 per month, while Romy has brought it down to ₹12,000.

Romiplostim represents the standard of care, but has been available only internationally since 2008. It is estimated that around 42,000 patients are diagnosed with ITP in India every year. Less than 10 per cent of patients have access to the treatment, which is required to maintain adequate platelet counts for a longer duration.

Published on July 10, 2019
This article is closed for comments.
Please Email the Editor